الرئيسية / قاعدة البيانات / أبرز الشركات / Novartis

Novartis

Rank #100 on Forbes Global 2000 — View on Forbes

ملف الشركة

Novartis

الأدوية والتقنية الحيوية

http://www.novartis.com

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

الدولة

سويسرا

المقر

Basel

الرئيس التنفيذي

Vasant Narasimhan

القطاع

الأدوية والتقنية الحيوية

الموظفون

75,883

الإيرادات

$50,315M

الأرباح

$11,948M

الأصول

$106,763M

سنة التأسيس

١٩٩٦

جميع التقارير تقارير الاستدامة الشاملة

Q2 2025 Impact and Sustainability Update to investors

تقارير الاستدامة الشاملة

Novartis

Novartis

Q2 2025 Impact and Sustainability Update to investors

Novartis in Society Integrated Report 2024

Annual Report 2024 Corporate Governance

Impact & Sustainability: Novartis 11th Annual ESG Investor Event

Reporting Criteria for Novartis in Society Integrated Report 2024

Novartis in Society Integrated Report 2024

Report on Child Labor Due Diligence in Our Supply Chain 2024

Sustainability-linked bond 2024 report

Novartis SASB Index 2024

Integrated Report 2024

Q4 2024 Impact and Sustainability Update

Transparency Act Statement 2024

Novartis in Society Integrated Report 2023

Integrated Report 2022

Annual Report 2016

Annual Report 2015

Annual Report 2011

Annual Report 2010

Annual Report 2007

Annual Report 2006

Annual Report 2005

Annual Report 2004

Novartis Position on Medicines for Patients with Rare Diseases

ESG Index: Innovation

Novartis Position on Falsified Medical Products

Novartis Position on Responsible Clinical Trials

Novartis Commitment to Diversity in Clinical Trials

Novartis Position on Animal Research

Novartis Position on innovative Biologic Medicines and Biosimilars

Clinical Study Transparency: Clinical Study Registration, Results Reporting and Data Sharing

Environmental Sustainability

Human Rights Commitment Statement

Novartis Position on innovative Biologic Medicines and Biosimilars

Novartis Position on Pharmaceuticals in the Environment

Novartis Organizational Structure

Novartis Position on Collaborating with Patient Organizations

ESG Index: Access to medicines

Novartis Position on Pharmaceuticals in the Environment

Environmental Sustainability Criteria for Suppliers

Novartis Environmental Sustainability Strategy

Our Code of Ethics

Human Rights Commitment Statement

Modern Slavery Statement 2024 - Australia, Canada, and United Kingdom